
    
      The aim of this trial is to compare the degree of efficacy, safety and tolerability of CG 428
      cutaneous solution versus placebo on prevention of chemotherapy induced alopecia (CIA) in
      female patients with metastatic cancer treated with selected regimens inducing alopecia.
    
  